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Most vascular diseases are characterized by an increase in
the production of reactive oxygen species (ROS). The
resulting oxidative stress reduces the biological activity of
endothelial-derived nitric oxide (NO). In the present
study we have evaluated the responsiveness of sGC in cells
exposed to HMR1766, a NO-independent sGC activator
that preferentially stimulates the oxidized/heme-free
enzyme. Pre-treatment of rat aortic smooth muscle cells
(RASMC) with 500 μM of H2O2 reduced the ability of
both sodium nirtroprusside (SNP; a nitric oxide donor)
and BAY 41–2272 (a NO-independent, heme-dependent
sGC activator) to increase intracellular cGMP levels. In
contrast, pre-treatment of cells with H2O2 significantly
increased the HMR1766-stimulated cGMP accumulation.
Similarly, pre-treatment of RASMC with SIN-1 (500 μM),
a peroxynitrite donor, enhanced sGC activation by
HMR1766. Adenovirus-mediated overepxression of cata-
lase or superoxide dismutase in RASMC did not alter the
responsiveness to HMR1766. To study if HMR1766 stim-
ulates cGMP accumulation in cells expressing heme-defi-
cient sGC we generated histidine 105 to phenylalanine
(H105F) or cycteine (H105C) mutants of the sGC β1 sub-
unit. In wild-type sGC-expressing cells NO-stimulated
cGMP accumulation was blocked by ODQ, while
HMR1766-stimulated cGMP was enhanced by ODQ. The
H105F mutant was not sensitive to NO, as it is heme-defi-
cient, but exhibited a 10-fold increase in cGMP accumula-
tion after stimulation with HMR1766; this effect of
HMR1766 was not affected by ODQ pretreatment. The
α1/H105C enzyme was basally much more active than wt
sGC and could be further stimulated with HMR1766, but
not SNP. The above data indicate that HMR1766 is capa-
ble of activating oxidized and heme-free sGC in vivo.
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